摘要
目的观察贝伐单抗联合化疗治疗Ⅳ期左右半结肠癌临床疗效。方法对我院2012年1月~2017年1月收治的57例经贝伐单抗联合化疗治疗的Ⅳ期左右半结肠癌患者进行回顾性分析,比较左、右半结肠癌患者的临床特征、临床受益率(CBR)、无进展生存时间(PFS)及总生存时间(OS)。结果Ⅳ期右半结肠癌(RSCC)患者中高龄及女性患者更常见,更易合并体重下降(P=0.041)及贫血(P=0.639),且出现CEA(P=0.038)及CA199(P=0.027)异常升高的患者所占比例更高,而左半结肠癌(LSCRC)患者中合并肠梗阻的比例更高(P=0.882)。腹腔种植转移及多脏器转移患者所占比例RSCC高于LSCRC(P=0.426,P=0.579)。RSCC与LSCRC患者CBR分别为70.00%和96.30%,差异有统计学意义(P=0.024);LSCRC患者中位PFS和OS均优于RSCC患者(10个月vs 5个月,P=0.035;25个月vs 21个月,P=0.001)。结论贝伐单抗联合化疗治疗Ⅳ期左右半结肠癌临床疗效较好,但右半结肠癌患者预后差于左半结肠癌患者。
Objective To observe the clinical efficacy of bevacizumab combined with chemotherapy in the treatment of stage IV colon cancer.Methods A retrospective analysis of 57 patients with stage IV colon cancer who were treated with bevacizumab and chemotherapy in our hospital from January 2012 to January 2017 was performed to compare the clinical features of patients with left and right colon cancer.Clinical benefit rate(CBR),progression-free survival(PFS),and overall survival(OS).Results Patients with advanced stage IV colon cancer(RSCC)were more common in older patients(P=0.038)and females(P=0.653),and were more likely to have weight loss(P=0.041)and anemia(P=0.639),Patients with abnormally elevated CEA(P=0.038)and CA199(P=0.027)had a higher proportion,while patients with left colon cancer(LSCRC)had a higher proportion of intestinal obstruction(P=0.882).The percentage of RSCC in patients with peritoneal implant metastasis and multiple organ metastasis was higher than that in LSCRC(P=0.426,P=0.579).The CBR of patients with RSCC and LSCRC were 70.00%and 96.30%,respectively,and the difference was statistically significant(P=0.024).The median PFS and OS of patients with LSCRC were better than those of RSCC(10 months vs.5 months,P=0.035;25 months vs.21 months,P=0.001).Conclusion Bevacizumab combined with chemotherapy for the treatment of stage IV colon cancer is better,but the prognosis of patients with right colon cancer is worse than that of patients with left colon cancer.
作者
常颖慧
赵晓辉
高蔚然
王季堃
CHANG Ying-hui;ZHAO Xiao-hui;GAO Wei-ran;WANG Ji-kun(Department of Oncology,the First Affiliated Hospital of Jinzhou Medical University,Jinzhou 121001,Liaoning,China)
出处
《医学信息》
2019年第8期119-122,共4页
Journal of Medical Information